NEUROONE MEDICAL TECHNOLOGIES CorpNMTC
時価総額
$3580.5万
PER
神経疾患向け医療機器開発の新興企業。皮質ストリップ、グリッド、深部電極の薄膜マイクロ電極技術を展開。2024年8月の私募で約265万ドルを調達、同年10月に大手医療機器企業と排他的開発・販売契約を締結。米国中心に展開。
| 2011年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2019年 9月30日 | 2020年 9月30日 | 2021年 9月30日 | 2022年 9月30日 | 2023年 9月30日 | 2024年 9月30日 | |
| Cash and cash equivalents | - | - | - | - | 260,749 | 4 | 7 | 8 | 5 | 1 |
| Accounts receivable | - | - | - | - | - | - | 48,336 | 33,237 | - | 176,636 |
| Total | - | - | - | - | - | - | 98,287 | 704,538 | 2 | 3 |
| Deferred offering costs | - | - | - | - | - | - | - | - | - | 142,633 |
| Prepaid expenses | - | - | - | - | - | - | - | - | - | 216,461 |
| Total current assets | 13,851 | 205 | 1,838 | - | 301,751 | 4 | 7 | 12 | 7 | 5 |
| Net Intangibles, beginning | - | - | - | - | 178,838 | 156,523 | 134,207 | 111,892 | 89,577 | 67,262 |
| Right-of-use asset | - | - | - | - | - | 282,211 | 288,948 | 181,355 | 169,059 | 254,910 |
| Property and equipment, net | - | - | - | - | 52,026 | 166,031 | 223,329 | 353,599 | 525,753 | 416,843 |
| Total assets | 13,851 | 205 | 1,838 | 4,277 | 532,615 | 5 | 8 | 13 | 8 | 5 |
| Accounts payable | - | 9,966 | 16,659 | 22,362 | 1 | 762,538 | 528,829 | 927,662 | 685,104 | 1 |
| Total | - | 3,000 | - | - | 617,721 | 512,762 | 644,249 | 715,839 | 1 | 1 |
| Total current liabilities | 4,628 | 35,594 | 83,330 | 117,927 | 2 | 2 | 1 | 3 | 2 | 2 |
| Balance as of beginning of year | - | - | - | - | - | - | - | - | - | 2 |
| Operating lease liability, long term | - | - | - | - | - | 254,328 | 202,895 | 119,556 | 55,284 | 194,392 |
| Total liabilities | 17,128 | 35,594 | 83,330 | 117,927 | 2 | 3 | 1 | 3 | 2 | 5 |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding. | - | - | - | - | - | - | - | - | - | - |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 30,816,499 and 23,928,945 shares issued and outstanding as of September 30, 2024 and 2023, respectively. | 5,073 | 5,073 | 5,073 | 5,073 | 13,494 | 22,181 | 35,834 | 16,217 | 23,929 | 30,816 |
| Additional paid–in capital | 28,077 | 76,723 | 93,483 | 45,577 | 16 | 33 | 47 | 60 | 69 | 76 |
| Accumulated deficit | - | - | -180,048 | -227,823 | -17,238,871 | -30,879,031 | -40,827,199 | -50,826,812 | -62,686,303 | -75 |
| Total stockholders’ equity | -3,277 | -35,389 | -81,492 | -113,650 | -1,237,578 | 2 | 7 | 10 | 6 | 822,013 |
| Total liabilities and stockholders’ equity | 13,851 | 205 | 1,838 | 4,277 | 532,615 | 5 | 8 | 13 | 8 | 5 |